VIB Discovery Sciences: linking academia to pharma

Maarte Dewilde

Expert Scientist Biologics

Non-confidential

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

VIB’s mission

“Excellence in Science and Technology”

“Excellence in Innovation and Business”

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

VIB scientists achieve the global top via high impact publications

In Medicine

Times Higher Education Ranking VIB ranks nr 1 on patent citations

• Survey of Times Higher Education in Aug 2015 ranks VIB on 1st place for patent citactions amongst research institutes

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Industrial income 2017: a record year

Total: 28.7 M€

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

VIB start-ups – very visible impact

€ € € 1,2B€

total investment

3,9B€ Ablynx

+ Non-Equity Deal-money

AELIN THERAPEUTICS

823 employees

* *

*

*

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Aelin Therapeutics launched with 27M Series A

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Truly innovative, high-impact science is the basis for transformative medicines,...

• “Today’s most transformative medicines exist because of fundamental discoveries that were made without regard to practical outcome and with their relevance to therapeutics only appearing decades later.”

• “….We found that approximately 80% of the medicines… could be traced back to one or several basic discoveries,…”

Source: Nature Drug Discovery Kneller, 2010 Source: Science Translational Medicine, Spector, Harrison & Fishman, 2018

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

...but high-impact science alone is not sufficient

Capabilities

Expertise

Infrastructure

Drug discovery projects

Biomedical example Similar in Agro

Return on investment Impact for patients

‘Valley of Death’ = ‘A window of opportunity’

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

• Validation of IP

• In-licensing assets

• Combination of IP/assets

• Small equity investment

• Endorsement of VIB’s commitment

Sciences:

• From innovative targets towards novel pharmacology

• Industry-trained discovery team

• Early stage venture fund

• Increase output of novel innovative ventures

VIB intensifies focus on Impact

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

• Our mission: Identifying & challenging the true potential of the scientific insights

Starting the journey of innovation

• Achieving Impact: Requires proof-of-concept,...

...and translational research

• Create a synergistic culture of basic science and drug discovery

VIB intensifies focus on Impact

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Project Selection

• Scientific rational & novelty

• Clinical relevance & need

• Status of target validation

• Business & societal impact

• Competitive position & IP landscape

• Target Product Profile

IS IT REAL & SHOULD WE DO IT ?

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Project Selection

• Academic research lab prepared to co-invest

• Target sufficiently validated

• Availability of assays, technologies, tools, in vivo models, ...

• Define screening cascade & assay development

• Key uncertainties in the project

• Co-investing third party

• External funding opportunities

IS IT FEASIBLE ?

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Setup for early drug discovery

• State-of-the-art infrastructure • Bio-Incubator • fully integrated screening platform • DD infrastructure geared towards

Assay Development & Biologics

• VIB Technology Centers – Core Facilities

• Synergistic partners on project-by-project basis

• Industry-experienced Scientists

• + Budget for experimental work

SME

biological

Agro

Commercialisation of VIB Science

De-risk the target • Demonstrate robustness

• Demonstrate druggability

• Demonstrate pharmacological effect

• Develop assays and tools for discovery projects

Generate Proprietary Molecules • Potent and selective Candidate Molecules

• Functional characterisation

• Proof-of-concept In vivo model / human / in planta model

Generate confidence in disease/phenotype association

• Proprietary IP on compounds / biologics

Translational aims

Impact to Society

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186 Common biology

Next generation Therapeutics

Technology platform

Single therapeutic asset venture

License

Pressure test exciting target biology:

Reproducibility & tractability

Investor-ready proof-of-principle

Co-development on innovative targets

Capital efficient through co-investment or in-kind contributions

External partners

End goal: Creating options for commercialisation

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

G-Secretase-stabilizers: An innovative drug discovery partnership to derisk a truly innovative hypothesis on the target validity

Option

VIB Driven Commericalisation

In-kind support: Library (blinded) antibody

Assay development & screening

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

BACE1 inhibiting mAb: therapeutic licensing

discovery Benchmarking & deal negotiations

-1 0 -8 -6 -4

-5 0

0

5 0

1 0 0

1 5 0

M B P -C 1 2 5 s w E L IS A

C o n c e n tra tio n

Inh

ibit

ion

(%

)B e n c h m a rk

m A b 1 A 1 1

BBB crossing variant Development and commercialization

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

MALT1: therapeutic licensing

Diagnostic Patent Application

Composition of matter IP

Screening Patent

Basic biology series of small molecule inhibitors

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Creating a start-up Company with an exciting pipeline

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Creating an Impact-investor funded start-up Company

+ Subcontractors

CMT-dedicated start-up

company

Patient Impact Biopontis Portfolio Company

Impact investors Charity funders Grant funding

VC funding

+ Patient involvement

Pharma partner involvement

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

Target validation Assay devt Hit generation Hit-to-Lead POC Target Discovery

• MALT1 inhibitors for treatment of T- and B-cell inflammation & lymphoma

• Biologicals in Alzheimer’s Disease Licensed

• HINT1 pharmacoperones in type 2 Charcot-Marie Tooth Disease Licensed

VIB’s Drug Discovery pipeline - Partnered

Licensed

• Next generation Immune-Oncology Biologicals

Licensed

• Next generation Immune-Oncology Biologicals

• Next generation Immune-Oncology Biologicals

• Next generation Immune-Oncology Biologicals

• Next generation Immune-Oncology Biologicals

• sdAb’s for Immuno – Prophylaxis/ Therapy in viral infections

• sdAb’s for Immuno – Prophylaxis/ Therapy in viral infections

• Novel target in Alzheimer’s Disease Optioned

Under discussion

• ɣ-Secretase sub-type specific modulators in Alzheimer’s Disease Licensed

CONFIDENTIAL

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

• Kinase inhibitor program in allergic asthma

• Metabolism modulators in Immuno-Oncology & IR injury

• Targeting strategies in Asthma / Atopic Dermatitis

• Specific Signaling inhibitors in Oncology

• aggregation pathway targeting

• blocking biologicals in inflammation-associated bone loss

• Immunometabolism targets overcoming Immune Resistance

VIB’s Drug Discovery pipeline - Unpartnered

• N-terminal TAU inhibition program in Alzheimer’s Disease

Target validation Assay devt Hit generation Hit-to-Lead POC Target Discovery

• biologics in aTNF-resistant Rheumatoid Arthritis or OsteoArthritis

• Anti-biofilm molecules as aduvant therapy in Antibiotic treatment

CONFIDENTIAL

• Disease Modifying strategies in CMT: 2 unpublished projects

Corporate VC Diligence

VC Diligence

• BBB crossing technology development

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

VIB start-up portfolio – realized

° 1996, RNAi company -> agro IPO 2005 2012 Syngenta acquisition ($522M) R&D center in Flanders

° 1998, 2006 BASF acquisition (96M Euro) R&D center in Flanders (2016)

° 2001, 2007 Euronext IPO 2017 NASDAQ IPO 3,9B Euro offer by Sanofi (2018) Operations in Gent (#490)

° 2006 Live biotherapeutics 2015 acquisition by Intrexon ($60M) Intrexon Actobiotics unit in Gent (#33)

°2006 Diagnostics / proteomics 2014 acquisition by Biocartis Mycartis spin-out Operations in Gent (#43)

°2011 Diagnostics / NGS kits 2016 acquisition by Agilent (68M Euro) Multiplicom subsidiary in BE

°2011 ; CMO Acquired by Amatsi, then EuroFins Operations in Gent / GMP facility

R:255 G:104 30

R:90 G:42 B:130

R:124 G:124 B:124

R:27 G:41 B:68

R:66 G:183 B:186

VIB start-up portfolio - active

°2013 Agrobodies for crop protection Series B of 11M Euro led by Sofinnova

°2015 Clinical asset TB-403 for medulloblastoma Pipeline of IO assets Thrombogenics – VIB JV

°2015 Reprogramming the immune system in IO and beyond Genome scale SM discovery US-BE transatlantic structure

°2015 VIB affiliated venture fund 75M Euro Invests in agro, diagnostics, biopharmaceutical,

°2016 Superior micro-organisms for sustainable agriculture 7,7M Euro Series A

°2015 Superior GPCR drug discovery Confobodies as stabilizing tools for GPCRs 6,7M Euro Series A round deals with Roche ; Lundbeck

°2017 Novel therapeutic modality based on protein aggregation Anti-infectives / oncology 27M Series A round LSP; NVF; PMV; BIVF; Fund+

°2015 Superior industrial yeast strains for bio-based economy Belgian – Brazilian biotech Launched with 6,25M Euro